Last reviewed · How we verify
Rectal bacteriotherapy
Rectal bacteriotherapy involves the administration of beneficial bacteria to the rectum to restore the balance of gut microbiota.
Rectal bacteriotherapy involves the administration of beneficial bacteria to the rectum to restore the balance of gut microbiota. Used for Treatment of Clostridioides difficile infection.
At a glance
| Generic name | Rectal bacteriotherapy |
|---|---|
| Sponsor | Hvidovre University Hospital |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | Phase 3 |
Mechanism of action
This approach aims to alleviate symptoms of conditions such as irritable bowel syndrome (IBS) by promoting a healthy gut environment. The beneficial bacteria help to crowd out pathogenic bacteria, reducing inflammation and improving digestion.
Approved indications
- Treatment of Clostridioides difficile infection
Common side effects
- Abdominal pain
- Diarrhea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rectal bacteriotherapy CI brief — competitive landscape report
- Rectal bacteriotherapy updates RSS · CI watch RSS
- Hvidovre University Hospital portfolio CI